B.Desvergne Archive


Public thesis defence of Matthew Hall

Matthew Hall will defend his PhD thesis entitled: “PPARbeta a player in astrocyte metabolism and morphology”, directed by Prof. Béatrice Desvergne, on June 10th at 16h30 in the amphi A of the Génopode.



Welcome to Mariano Schiffrin and Nourhène Khaled

Mariano Schiffrin will join Prof. Béatrice Desvergne’s lab on May 1st as a PhD Student to work on his project entitled: “PPARS Function on Mesenchymal Stem Cell Differentiation and Bone Metabolism”.

Nourhène Khaled will come back at the CIG on May 1st in Prof. Walter Wahli’s lab as a Intern to work on the role of PPARs on Metabolism. Last year, Nourhène was working as a Master Student with Prof. Walter Wahli.


Welcome to Linda Müller, a new master student

Linda Müller will join Prof. Béatrice Desvergne‘s group as a master student on March 17th, 2011. She will be working on her master thesis entitled: “Tsukushin: a novel common target gene of liver metabolism and regulators” under the supervision of Dr Cristina Casals Casas.


Good luck to Cristina Leoni, Jean-Gaël Diserens and Nourhène Khaled

Cristina Leoni, Jean-Gaël Diserens and Nourhène Khaled arrived at the CIG on February 22nd, 2010  as master Student to work in Dr Liliane Michalik’s, Prof. Béatrice Desvergne’s and Prof. Walter Wahli’s group.

After having succeeded their master exam, they left the CIG at the end of January 2011. We wish them all the best !


Good luck to Laure Quignodon

Laure Quignodon arrived at the CIG on October 1st, 2007 as a Postdoc in Prof. Béatrice Desvergne‘s group.

She is leaving the CIG on January 31st, 2011 to start working at the University of Geneva and the University Hospital of Geneva as the animal house Manager.

We wish her all the best for her future !


Welcome to Mariagiovanna Parente

Mariagiovanna Parente will be working in Prof. Desvergne‘s group as an Intern from January 17th, 2011 to July 16th, 2011. She is currently preparing her PhD thesis at the University of Bari, Italy on the following subjects: new PPARs ligands, useful for the treatment of pathologies such as: obesity, type II diabetes, heart failure and cancer.